Skip to content Skip to sidebar Skip to footer
Subscribe Now
The Critical Significance of Early Orthodontic Intervention During Adolescence
THOUGHTSPOT

The Critical Significance of Early Orthodontic Intervention During Adolescence

Adolescence presents a crucial window for orthodontic care due to the rapid development of bones, muscles and facial structure. During this stage, the jaw and dental arches are still forming, allowing orthodontists to guide growth patterns more effectively than during adulthood. When issues like misalignment, crowding or improper bite are identified early, intervention can redirect…
May 12, 20250Comments

Read more

Strategies for enhancing comfort with clear aligners
THOUGHTSPOT

Strategies for enhancing comfort with clear aligners

Clear aligners have revolutionized orthodontic care, offering a discreet and flexible alternative to traditional braces. However, managing discomfort during the adjustment phase is crucial for a successful treatment experience. The increasing popularity of clear aligners in orthodontic treatment is evident. This innovative approach offers aesthetic appeal and convenience, making it a preferred choice for many.…
May 12, 20250Comments

Read more

Bayer
News

Bayer Submits MAA of Eylea 8mg to Japan’s MHLW for Treating Macular Edema Secondary to Retinal Vein Occlusion (RVO)

Shots: Japan’s MHLW has received MAA for Eylea 8mg (114.3mg/ml for injection) to treat pts with macular edema following RVO (central, branch & hemiretinal) supported by the P-III (QUASAR) trial; regulatory filings are ongoing in other markets In the trial, Eylea 8mg (Q8W after 3 or 5 monthly doses) met its 1EP at 36wks. with…
May 12, 20250Comments

Read more

Lenz Therapeutics and Lotus
News

LENZ Therapeutics Collaborates with Lotus Pharmaceutical to Commercialize LNZ100 in the Republic of Korea and Southeast Asia

Shots: LENZ has granted Lotus exclusive development, manufacturing, registration & marketing rights of LNZ100 to treat presbyopia in the Republic of Korea & certain Southeast Asian countries incl. Thailand, Philippines, Vietnam, Malaysia, Brunei, Indonesia & Singapore As per the deal, LENZ will obtain ~$125M in upfront, regulatory & commercial milestones, along with double-digit net sales-based…
May 12, 20250Comments

Read more

Astrazeneca
News

AstraZeneca Reports P-III (POTOMAC) Trial Findings of Imfinzi Regimen for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Shots: AstraZeneca has reported P-III (POTOMAC) trial findings assessing Imfinzi in 1018 high-risk, BCG-naïve NMIBC pts post-TURBT, randomized to Imfinzi + BCG induction & maintenance, Imfinzi + BCG induction-only, or SoC BCG therapy Imfinzi + BCG induction & maintenance therapy showed improved disease-free survival (DFS; 1EP) vs SoC BCG, while Imfinzi + BCG induction-only did…
May 12, 20250Comments

Read more

Weekly Snapshot

PharmaShots Weekly Snapshots (May 05, 2025 – May 09, 2025) 

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, Biosimilar & Animal Health. Check out our full report below:    Recursion Presents Preliminary P-Ib/II (TUPELO) Trial Data of REC-4881 for Familial Adenomatous Polyposis (FAP) at DDW 2025  Read More: Recursion  Chengdu Origen and Vanotech Report the First Patient Dosing in P-I (VAN-2401)…
May 9, 20250Comments

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]